REPORTS

Let’s Pullulate and Expand Your Business

Glucagon Like Peptide-1 (Glp-1) Agonists Market - Global Professional Analysis and Forecast to 2026

Oct 24, 2019  |  220 PAGES  |  REPORT CODE: CMM222696
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Glucagon Like Peptide-1 (Glp-1) Agonists market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 13.3% during the forecast period.

This report presents the market size and development trends by detailing the Glucagon Like Peptide-1 (Glp-1) Agonists market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Glucagon Like Peptide-1 (Glp-1) Agonists market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Glucagon Like Peptide-1 (Glp-1) Agonists industry and will help you to build a panoramic view of the industrial development.

Glucagon Like Peptide-1 (Glp-1) Agonists Market, By Type:

  • Lixisenatide

  • Liraglutide

  • Exenatied

Glucagon Like Peptide-1 (Glp-1) Agonists Market, By Application:

  • Pharmacy

  • Hospital

  • Others

Some of the leading players are as follows:

  • Bristol-Myers Squibb

  • Amylin

  • Eli Lily

  • Sanofi

  • Novo Nordisk

  • AstraZeneca

  • GSK

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Glucagon Like Peptide-1 (Glp-1) Agonists Market: Technology Type Analysis

  • 4.1 Glucagon Like Peptide-1 (Glp-1) Agonists Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Glucagon Like Peptide-1 (Glp-1) Agonists Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Lixisenatide

    • 4.3.2 Liraglutide

    • 4.3.3 Exenatied

5 Glucagon Like Peptide-1 (Glp-1) Agonists Market: Product Analysis

  • 5.1 Glucagon Like Peptide-1 (Glp-1) Agonists Product Market Share Analysis, 2018 & 2026

  • 5.2 Glucagon Like Peptide-1 (Glp-1) Agonists Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Glucagon Like Peptide-1 (Glp-1) Agonists Market: Application Analysis

  • 6.1 Glucagon Like Peptide-1 (Glp-1) Agonists Application Market Share Analysis, 2018 & 2026

  • 6.2 Glucagon Like Peptide-1 (Glp-1) Agonists Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Pharmacy

    • 6.3.2 Hospital

    • 6.3.3 Others

7 Glucagon Like Peptide-1 (Glp-1) Agonists Market: Regional Analysis

  • 7.1 Glucagon Like Peptide-1 (Glp-1) Agonists Regional Market Share Analysis, 2018 & 2026

  • 7.2 Glucagon Like Peptide-1 (Glp-1) Agonists Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Bristol-Myers Squibb

    • 9.1.1 Bristol-Myers Squibb Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Amylin

    • 9.2.1 Amylin Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Eli Lily

    • 9.3.1 Eli Lily Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi

    • 9.4.1 Sanofi Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Novo Nordisk

    • 9.5.1 Novo Nordisk Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 AstraZeneca

    • 9.6.1 AstraZeneca Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 GSK

    • 9.7.1 GSK Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

 

The List of Tables and Figures (Totals 79 Figures and 127 Tables)

  • Figure Lixisenatide Glucagon Like Peptide-1 (Glp-1) Agonists market, 2015 - 2026 (USD Million)

  • Figure Liraglutide Glucagon Like Peptide-1 (Glp-1) Agonists market, 2015 - 2026 (USD Million)

  • Figure Exenatied Glucagon Like Peptide-1 (Glp-1) Agonists market, 2015 - 2026 (USD Million)

  • Figure Pharmacy market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Glucagon Like Peptide-1 (Glp-1) Agonists market, by country, 2015 - 2026 (USD Million)

  • Table North America Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table North America Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table North America Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Canada Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Canada Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Europe Glucagon Like Peptide-1 (Glp-1) Agonists market, by country, 2015 - 2026 (USD Million)

  • Table Europe Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Europe Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Europe Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Germany Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Germany Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table France Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table France Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Italy Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Italy Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Spain Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Spain Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Glucagon Like Peptide-1 (Glp-1) Agonists market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table China Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table China Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Japan Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Japan Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table India Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table India Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Glucagon Like Peptide-1 (Glp-1) Agonists market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table MEA Glucagon Like Peptide-1 (Glp-1) Agonists market, by country, 2015 - 2026 (USD Million)

  • Table MEA Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table MEA Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table MEA Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Glucagon Like Peptide-1 (Glp-1) Agonists market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Glucagon Like Peptide-1 (Glp-1) Agonists market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Glucagon Like Peptide-1 (Glp-1) Agonists market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amylin Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lily Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GSK Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top